Numerous research teams all over the world are participating in the race to develop a vaccine for COVID-19. Many of them at this point is focusing on the way the virus presents itself in animals, with the biggest hurdle being the way it morphs when it moves from animals to human beings.

Scientists in Israel are likely to announce vaccines developed for coronavirus.

The Institute for Biological Research, located in the central Israeli town of Nes Tziona, was established in 1952 as part of the Israel Defence Forces’ Science Corps, and later became a civilian organization.

Prime Minister Benjamin Netanyahu is said to have ordered the institute to devote resources to develop a vaccine for Covid-19 on Feb 1.

Israeli daily Ha’aretz reported on Thursday that scientists at Israel’s Institute for Biological Research, supervised by the Prime Minister’s office, have recently had a significant breakthrough in understanding the biological mechanism and qualities of the virus, including better diagnostic capability, production of antibodies for those who already have the virus and development of a vaccine.

An effective Israeli-developed vaccine for coronavirus is on track to be ready for testing within “a few weeks,” though it won’t be available for months because of the lengthy and sometimes bureaucratic testing and approval process.

What does the vaccine consist of?

The vaccine will consist of a specially produced protein. They have developed proteins that are needed for the technology of oral vaccination. They are special proteins that, when sprayed into the mouth, penetrate the epithelial cells inside the mouth and activate a mucosal immune response, which is the part of the immune response in our body that protects the entry point of the virus.

Much of the work is done by bacteria, as the compounder takes the virus DNA and introduces it to bacteria and makes the bacteria produce the viral proteins.

China released the genetic sequence of the virus on open scientific databases shortly after its outbreak in January so that research institutes and commercial companies could try to develop treatments and vaccines without requiring to obtain samples.

Any vaccine developed in Israel will presumably also need to go through a similar or even stricter process before it will be approved for use.

The pandemic has catalyzed the development of novel coronavirus vaccines across the biotech industry, both by pharmaceutical companies and research organizations such as the National Institutes of Health (NIH), US.

Also read :

Favilavir, the first approved coronavirus drug in China

The National Medical Products Administration of China has approved the use of Favilavir, an anti-viral drug, as a treatment for coronavirus. The drug has reportedly shown efficacy in treating the disease with minimal side effects in a clinical trial involving 70 patients. The clinical trial is being conducted in Shenzhen, Guangdong province.

Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine by MIGAL Research Institute (Israel)

The MIGAL Research Institute in Israel announced that an Infectious Bronchitis Virus (IBV) vaccine developed to treat avian coronavirus has been modified to treat Covid-19. The vaccine has demonstrated efficacy in pre-clinical trials conducted by the Volcani Institute.

The IBV vaccine was developed after four years of research and has high genetic similarity to the human coronavirus. The institute has genetically modified the vaccine to treat Covid-19 and will be available in the oral form.

The institute is currently exploring potential partners for producing the vaccine in the next eight to ten weeks and obtaining the necessary safety approvals for in-vivo testing.